Trials / Completed
CompletedNCT01954004
Open Registry Measuring Impact of Genomic Testing on Treatment of Prostate Cancer Patients
An Open Registry to Measure the Impact of Adding Genomic Testing (Prolaris®) on the Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 1,270 (actual)
- Sponsor
- Myriad Genetic Laboratories, Inc. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This registry is intended to evaluate the impact of genomic test results towards selecting a first-line therapy option for newly diagnosed localized prostate cancer patients.
Conditions
Timeline
- Start date
- 2013-04-01
- Primary completion
- 2014-09-01
- Completion
- 2014-09-01
- First posted
- 2013-10-01
- Last updated
- 2015-06-02
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01954004. Inclusion in this directory is not an endorsement.